my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Company Portrait
Affimed is a private biopharmaceutical company specializing in the development of recombinant antibodies.
Industrial Sectors
Watchlist
This is where you can add this company to your personal favourites
Affimed enrolls first patients in Phase I Hodgkin's Lymphoma Study
Affimed Therapeutics AG announced that the first patients with Hodgkin's Lymphoma have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. The Phase I repeat dose escalation study will enroll approximately 40 Hodgkin's Lymphoma patients across two centers in Europe and ... more
Affimed Therapeutics AG expands clinical development team
In preparation for the clinical entry of its first product candidate Affimed Therapeutics AG expands its development team with an experienced expert. Effective immediately, Dr Christian Hucke takes over responsibility for planning and implementation of the clinical development programs at A ... more
Affimed joins the Molecular Imaging Technology Initiative
Affimed Therapeutics AG announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and other partners within the Molecular Imaging Technology Initiative launched by the German Federal Ministry of Education and Research (“BMBF”). A ... more
Affimed is a private biopharmaceutical company specializing in the development of recombinant antibodies. more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
Companies
